Epileptogenic Tubers Are Associated with Increased Kurtosis of Susceptibility Values: A Combined Quantitative Susceptibility Mapping and Stereoelectroencephalography Pilot Study

References

1. 1.↵
   1. Nabbout R,
   2. Belousova E,
   3. Benedik MP, et al

   . Historical patterns of diagnosis, treatments, and outcome of epilepsy associated with tuberous sclerosis complex: results from TOSCA Registry. Front Neurol 2021;12:697467 doi:10.3389/fneur.2021.697467 pmid:34566842

   CrossRefPubMed
2. 2.↵
   1. Arya R,
   2. Tenney JR,
   3. Horn PS, et al

   . Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions. J Neurosurg Pediatr 2015;15:26–33 doi:10.3171/2014.10.PEDS14107 pmid:25360852

   CrossRefPubMed
3. 3.↵
   1. Fallah A,
   2. Guyatt GH,
   3. Snead OC, et al

   . Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis. PLoS One 2013;8:e53565 doi:10.1371/journal.pone.0053565 pmid:23405072

   CrossRefPubMed
4. 4.↵
   1. Fallah A,
   2. Rodgers SD,
   3. Weil AG, et al

   . Resective epilepsy surgery for tuberous sclerosis in children: determining predictors of seizure outcomes in a multicenter retrospective cohort study. Neurosurgery 2015;77:517–24; discussion 524 doi:10.1227/NEU.0000000000000875 pmid:26120800

   CrossRefPubMed
5. 5.↵
   1. Liu S,
   2. Yu T,
   3. Guan Y, et al

   . Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China. Brain 2020;143:570–81 doi:10.1093/brain/awz411 pmid:31953931

   CrossRefPubMed
6. 6.↵
   1. Specchio N,
   2. Pepi C,
   3. de Palma L, et al

   . Surgery for drug-resistant tuberous sclerosis complex-associated epilepsy: who, when, and what. Epileptic Disord 2021;23:53–73 doi:10.1684/epd.2021.1253 pmid:33720022

   CrossRefPubMed
7. 7.↵
   1. Park JT,
   2. Vaca GF

   . Stereo-EEG in tuberous sclerosis complex. Pediatr Neurol Briefs 2020;34:6 doi:10.15844/pedneurbriefs-34-6 pmid:32174749

   CrossRefPubMed
8. 8.↵
   1. Gallagher A,
   2. Grant EP,
   3. Madan N, et al

   . MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex. J Neurol 2010;257:1373–81 doi:10.1007/s00415-010-5535-2 pmid:20352250

   CrossRefPubMed
9. 9.↵
   1. Neal A,
   2. Ostrowsky-Coste K,
   3. Jung J, et al

   . Epileptogenicity in tuberous sclerosis complex: a stereoelectroencephalographic study. Epilepsia 2020;61:81–95 doi:10.1111/epi.16410 pmid:31860139

   CrossRefPubMed
10. 10.↵
    1. Altman NR,
    2. Purser RK,
    3. Post MJ

    . Tuberous sclerosis: characteristics at CT and MR imaging. Radiology 1988;167:527–32 doi:10.1148/radiology.167.2.3357966 pmid:3357966

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Zhang MN,
    2. Zou LP,
    3. Wang YY, et al

    . Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis. Seizure 2018;60:86–90 doi:10.1016/j.seizure.2018.06.011 pmid:29929111

    CrossRefPubMed
12. 12.↵
    1. Chen W,
    2. Zhu W,
    3. Kovanlikaya I, et al

    . Intracranial calcifications and hemorrhages: characterization with quantitative susceptibility mapping. Radiology 2014;270:496–505 doi:10.1148/radiol.13122640 pmid:24126366

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Ruetten PP,
    2. Gillard JH,
    3. Graves MJ

    . Introduction to quantitative susceptibility mapping and susceptibility weighted imaging. Br J Radiol 2019;92:20181016 doi:10.1259/bjr.20181016 pmid:30933548

    CrossRefPubMed
14. 14.↵
    1. Lorio S,
    2. Sedlacik J,
    3. So PW, et al

    . Quantitative MRI susceptibility mapping reveals cortical signatures of changes in iron, calcium and zinc in malformations of cortical development in children with drug-resistant epilepsy. Neuroimage 2021;238:118102 doi:10.1016/j.neuroimage.2021.118102 pmid:34058334

    CrossRefPubMed
15. 15.↵
    1. Jenkinson M

    . BET: MR-Based Estimation of Brain, Skull and Scalp Surfaces. In: Proceedings of the Annual Meeting of the Organization for Human Brain Mapping, Toronto, Ontario, Canada. June 12–16, 2005
16. 16.↵
    1. Liu T,
    2. Wisnieff C,
    3. Lou M, et al

    . Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping. Magn Reson Med 2013;69:467–76 doi:10.1002/mrm.24272 pmid:22488774

    CrossRefPubMed
17. 17.↵
    1. Liu T,
    2. Khalidov I,
    3. de Rochefort L, et al

    . A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed 2011;24:1129–36 doi:10.1002/nbm.1670 pmid:21387445

    CrossRefPubMed
18. 18.↵
    1. Karsa A,
    2. Punwani S,
    3. Shmueli K

    . An optimized and highly repeatable MRI acquisition and processing pipeline for quantitative susceptibility mapping in the head-and-neck region. Magn Reson Med 2020;84:3206–22 doi:10.1002/mrm.28377 pmid:32621302

    CrossRefPubMed
19. 19.↵
    1. Yushkevich PA,
    2. Piven J,
    3. Hazlett HC, et al

    . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006;31:1116–28 doi:10.1016/j.neuroimage.2006.01.015 pmid:16545965

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Centeno M,
    2. Tierney TM,
    3. Perani S, et al

    . Combined electroencephalography-functional magnetic resonance imaging and electrical source imaging improves localization of pediatric focal epilepsy. Ann Neurol 2017;82:278–87 doi:10.1002/ana.25003 pmid:28749544

    CrossRefPubMed
21. 21.↵
    1. Chari A,
    2. Adler S,
    3. Wagstyl K, et al

    . IDEAL approach to the evaluation of machine learning technology in epilepsy surgery: protocol for the MAST trial. BMJ Surg Interv Health Technol 2022;4:e000109 doi:10.1136/bmjsit-2021-000109 pmid:35136859

    Abstract/FREE Full Text
22. 22.↵
    1. Gillen KM,
    2. Mubarak M,
    3. Park C, et al

    . QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions. Ann Clin Transl Neurol 2021;8:877–86 doi:10.1002/acn3.51338 pmid:33704933

    CrossRefPubMed
23. 23.↵
    1. Yaghmaie N,
    2. Syeda WT,
    3. Wu C, et al

    . QSMART: quantitative susceptibility mapping artifact reduction technique. Neuroimage 2021;231:117701 doi:10.1016/j.neuroimage.2020.117701 pmid:33484853

    CrossRefPubMed
24. 24.↵
    1. Wang Y,
    2. Yuan L,
    3. Zhang S, et al

    . Fast ripples as a biomarker of epileptogenic tuber in tuberous sclerosis complex patients using stereo-electroencephalograph. Front Hum Neurosci 2021;15:680295 doi:10.3389/fnhum.2021.680295 pmid:34220475

    CrossRefPubMed
25. 25.↵
    1. Yu X,
    2. Ding P,
    3. Yuan L, et al

    . Cortico-cortical evoked potentials in children with tuberous sclerosis complex using stereo-electroencephalography. Front Neurol 2019;10:1093 doi:10.3389/fneur.2019.01093 pmid:31736846

    CrossRefPubMed
26. 26.↵
    1. Despouy E,
    2. Curot J,
    3. Denuelle M, et al

    . Neuronal spiking activity highlights a gradient of epileptogenicity in human tuberous sclerosis lesions. Clin Neurophysiol 2019;130:537–47 doi:10.1016/j.clinph.2018.12.013 pmid:30785010

    CrossRefPubMed